• Join
  • Login
  • Contact

Search abstracts

Therapeutic drug monitoring (tdm) for antituberculosis treatment safety: screening for isoniazid acetylator phenotype.

  • At: 2006 FIP Congress in Salvadore (Brazil)
  • Type: Poster
  • By: GONCALVES, J.C. (Fac Farmácia-UFRJ, Rio De Janeiro, Brazil)
  • Co-author(s): Neves de Miranda, Claudia (Fac Farmácia-UFRJ, RIO DE JANEIRO, Brazil)
    Carvalho Queiroz Melo, Fernanda (Fac. de Medinina - UFRJ, RIO DE JANEIRO, Brazil)
  • Abstract:

    Tuberculosis is the world’s second commonest cause of death from infectious disease, after HIV/AIDS. In Brazil, there were an estimated 116.000 new cases of tuberculosis in 2003. Regimens containing isoniazid (INH), rifampicin and pirazinamide are traditionally used first-line therapy for tuberculosis. However, acute or chronic hepatitis..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses